Tissue biology · ARA-290
ARA-290 (cibinetide): EPO-derived signaling without erythropoiesis
October 27, 2026 · 2 min read · Models: Rat, Mouse, Cell culture
ARA-290 is an 11-amino-acid peptide modeled on one face of erythropoietin (EPO). It was designed to separate EPO’s non-erythropoietic signaling from its effect on red blood cell production. Mechanistic work has centered on a proposed EPO receptor–CD131 heteromer and on inflammatory cytokine signaling in rodent and cell models.
A summary of published research for scientific reference. It is not product information or medical advice, and it does not describe or endorse use in humans or animals. Findings from cell culture and animal models often do not carry over to other systems.
Origin and design
In experimental injury models, EPO signaling has been linked to the survival of neurons, cardiomyocytes and renal cells. Using it as a research tool is complicated by its strong drive on red cell production. Brines and colleagues mapped this non-erythropoietic activity to the surface of EPO’s helix B. In 2008 (PNAS) they described short peptides derived from that region. ARA-290, the pyroglutamate helix B surface peptide, is the best-characterized of them.
The peptide does not bind the classical EPO receptor homodimer that drives erythropoiesis. Instead it is proposed to act through a heteromer of the EPO receptor and the β-common receptor (CD131) that is upregulated in injured or inflamed tissue.
What animal studies report
In rodent models of peripheral nerve injury and diabetic neuropathy, investigators measured allodynia-like behavior and small-nerve-fiber density. In models of ischemic and inflammatory injury, they reported lower pro-inflammatory cytokine signaling.
The peptide’s half-life in these models is short (minutes), yet effects in some models outlast its presence. This has been interpreted as the peptide triggering a downstream signaling program rather than needing continuous receptor occupancy.
Open questions
Direct structural evidence for the EPOR–CD131 heteromer is still debated, and some effects of EPO-derived peptides have been reported in systems where CD131 contributes little. The questions most relevant to laboratory research concern receptor identity, downstream signaling and how far the rodent neuropathy findings generalize.
References
- Brines M, Patel NSA, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA. 2008;105(31):10925–10930.
- Brines M, Cerami A. The receptor that tames the innate immune response. Mol Med. 2012;18:486–496.
A summary of published laboratory research, for scientific information only. It is not medical advice and makes no claim about any material’s use. See the Website & Research Content Disclaimer.